CASI Stock Overview
A biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
CASI Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.68 |
| 52 Week High | US$8.19 |
| 52 Week Low | US$2.05 |
| Beta | 0.55 |
| 1 Month Change | -47.45% |
| 3 Month Change | -51.36% |
| 1 Year Change | -58.06% |
| 3 Year Change | -67.40% |
| 5 Year Change | -91.41% |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34%
Nov 26
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too
May 21Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%
Mar 12CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%
Dec 18We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate
Sep 02Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?
May 20Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M
Sep 23CASI Pharmaceuticals Q2 2022 Earnings Preview
Aug 11Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?
May 26Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts
Aug 14Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?
May 25Shareholder Returns
| CASI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.9% | -3.3% | -2.2% |
| 1Y | -58.1% | -1.9% | 23.9% |
Return vs Industry: CASI underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: CASI underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| CASI volatility | |
|---|---|
| CASI Average Weekly Movement | 15.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CASI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CASI's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 176 | Wei-Wu He | www.casipharmaceuticals.com |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company’s other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc
CASI Pharmaceuticals, Inc. Fundamentals Summary
| CASI fundamental statistics | |
|---|---|
| Market cap | US$39.88m |
| Earnings (TTM) | -US$30.96m |
| Revenue (TTM) | US$22.06m |
1.8x
P/S Ratio-1.3x
P/E RatioIs CASI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CASI income statement (TTM) | |
|---|---|
| Revenue | US$22.06m |
| Cost of Revenue | US$10.08m |
| Gross Profit | US$11.98m |
| Other Expenses | US$42.94m |
| Earnings | -US$30.96m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.06 |
| Gross Margin | 54.31% |
| Net Profit Margin | -140.40% |
| Debt/Equity Ratio | 138.1% |
How did CASI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 22:36 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CASI Pharmaceuticals, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Nathaniel Calloway | Edison Investment Research |
| Ching-Yi Lin | H.C. Wainwright & Co. |